Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,816 matching trials from the local directory fallback.
Filters: Phoenix, Arizona Clear all
Active, not recruiting Not applicable Interventional

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

NCT03706833
View directory record Official record
Conditions
Degenerative Mitral Valve Disease, Functional Mitral Regurgitation, Mitral Insufficiency, Mitral Regurgitation
Interventions
Abbott Mitraclip System, Edwards PASCAL System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 16, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
HIV Infections, Infection, Human Immunodeficiency Virus
Interventions
2 NRTIs plus an INI, NNRTI, or PI, Cabotegravir (CAB) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine (RPV) tablet, Rilpivirine - Injectable Suspension (RPV LA)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 16, 2026, 9:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Interventions
Placebo, TX000045- Dose A, TX000045- Dose B
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 30, 2026, 4:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
ADT, Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide
Other · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 5:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

NCT02775851
View directory record Official record
Conditions
Desmoplastic Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
280
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 15, 2026, 9:35 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Golcadomide, Placebo, Prednisone, Rituximab, Vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
46
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 4:33 PM EDT
Active, not recruiting Not applicable Interventional

A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

NCT02724371
View directory record Official record
Conditions
Breast Reconstruction, Revision Breast Reconstruction
Interventions
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 28, 2026, 11:33 PM EDT
Active, not recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247
View directory record Official record
Conditions
Leukemia
Interventions
Chemotherapy, Placebo, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 13, 2026, 9:57 PM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Organ Failure, Multiple, Red Blood Cell Transfusion
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Jul 28, 2026, 1:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Sep 30, 2026, 8:09 PM EDT
Active, not recruiting Phase 3 Interventional

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1403
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 5:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733
View directory record Official record
Conditions
Brain Neoplasms, Adult, Malignant, Brain Tumor, GBM, Glioblastoma
Interventions
Niraparib, Temozolomide
Drug
Lead sponsor
Ivy Brain Tumor Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 13, 2026, 4:16 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Duodenitis (EoD), Eosinophilic Gastritis (EoG), Eosinophilic Gastroenteritis, Eosinophilic Gastrointestinal Disease (EGID)
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 29, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Placebo, TS23
Drug
Lead sponsor
Translational Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 30, 2026, 4:20 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555
View directory record Official record
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 2:44 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 6:22 AM EDT
Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
View directory record Official record
Conditions
Breast Cancer
Interventions
No Radiation, Radiation
Other · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 8:11 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 13, 2026, 5:55 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Placebo, Seasonal Influenza Vaccine (SIV) (Flublok)
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Alzheimer's Disease Dementia, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 5, 2026, 8:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873
View directory record Official record
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
114
States / cities
Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 14, 2026, 12:51 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, Lung Transplant Infection, Lung Transplant; Complications
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 14, 2026, 11:29 PM EDT
Active, not recruiting Phase 2 Interventional

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
Parsaclisib, parsaclisib + ibrutinib, parsaclisib + itacitinib, parsaclisib + ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 11, 2026, 8:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxias
Interventions
Placebo, troriluzole
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 16, 2026, 12:27 AM EDT